Matthew Rosencranz is an associate in Goodwin’s Business Law department and a member of its nationally recognized Technology and Life Sciences groups.
Matthew advises companies on a wide array of corporate matters, including seed, venture and growth equity financings, public securities offerings, mergers and acquisitions, and other strategic and cross border transactions.
Matthew also represents growth equity and venture capital investors, advising them on structuring and executing their investment transactions.
He also advises clients on a range of ongoing SEC compliance matters and capital markets transactions, including initial public offerings and other equity offerings, tender offers, and PIPE transactions, and high yield, investment-grade and convertible debt offerings. He joined Goodwin in 2019.
Experience
Matthew’s representative clients, among others, include advising:
Technology:
- Allego
- Brightcove (Formerly NASDAQ: BCOV)
- Circle Internet Group (NYSE: CRCL)
- Dynatrace (NYSE: DT)
- Klaviyo (NYSE: KVYO)
- Mobeewave (sold to Apple)
- SmarterX
- Starburst Data
- Vatn Systems
Life Sciences:
- Boston Scientific (NYSE: BSX)
- Kymera Therapeutics Inc. (NASDAQ: KYMR)
- Moderna (Nasdaq: MRNA)
- MorphyoSys AG (Formerly NASDAQ: MOR)
- Obsidian Therapeutics
- Sensory Cloud
- TruDataRx
- Virex Health (sold to Sorrento Therapeutics)
Venture Capital and Growth Equity:
- Accel
- Curie.Bio
- DST Global
- Earlybird Ventures
- F-Prime
- Marshall Wace
- Mendon Venture Partners
- Milky Way Investments
- NEA: New Enterprise Associates
- Newlands
- Wellington Management Company
- Will Ventures
Professional Experience
While in law school, Matthew served as a judicial intern at the U.S. District Court for the District of Massachusetts and at the Massachusetts Supreme Judicial Court. He also served as an editor of the Suffolk University Law Review.
Credentials
Education
JD
Suffolk University Law School
BA
Saint Michael's College
Admissions
Bars
- Massachusetts